Publication

Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses

Journal Paper/Review - Oct 26, 2021

Units
Keywords
PubMed
Doi
Link
Contact

Citation
Schmiedeberg K, Vuilleumier N, Pagano S, Albrich W, Ludewig B, von Kempis J, Rubbert-Roth A. Efficacy and tolerability of a third dose of an mRNA anti-SARS-CoV-2 vaccine in patients with rheumatoid arthritis with absent or minimal serological response to two previous doses. Lancet Rheumatol 2021; 4:e11-e13.
Project
Type
Journal Paper/Review (English)
Journal
Lancet Rheumatol 2021; 4
Publication Date
Oct 26, 2021
Issn Print
Issn Electronic
2665-9913
Pages
e11-e13
Publisher
Brief description/objective